Previous 10 | Next 10 |
Imara (IMRA) has priced its public offering of common shares at $6.00/share, for gross proceeds of $50M.Underwriters' over-allotment is an additional $7.5M of shares.Closing date is July 16.Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the offering....
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, annou...
Imara (IMRA) announces that it has commenced a proposed underwritten public offering of $50M of shares.Intends to grant the underwriters a 30-day option to purchase up to an additional $7.5M of shares.Shares down 11% post market. For further details see: Imara shares slide on $50M ...
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today...
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Lau...
The following slide deck was published by IMARA Inc. in conjunction with this event. For further details see: IMARA (IMRA) EHA Investor Presentations - Slideshow
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the grant recipient...
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ET BOSTON, June 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq:...
Imara, Inc. (IMRA) Q1 2021 Earnings Conference Call April 11, 2021 08:30 ET Company Participants Michael Gray - Chief Financial Officer & Chief Operating Officer Rahul Ballal - President, Chief Executive Officer & Director Conference Call Participants Yigal Nochomovitz - Citigroup Mat...
News, Short Squeeze, Breakout and More Instantly...
IMARA Inc. Company Name:
IMRA Stock Symbol:
NASDAQ Market:
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” -- -- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stock...
NEW YORK, NY / ACCESSWIRE / January 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'...
There are plenty of ways to find the best penny stocks to buy. The first step, however, is knowing your idea of “best.” Everyone has a different style of trading and investing they subscribe to. Some look for entry opportunities to buy penny stocks and hold them long-term. O...